[摘要] 目的 探討丹參酮ⅡA對(duì)慢性肺源性心臟病急性加重期的療效及對(duì)患者腦鈉肽、D-二聚體水平的影響。 方法 選擇2015年1月～2017年1月收治的83例慢性肺源性心臟病急性加重期患者，分為研究組和對(duì)照組。對(duì)照組41例患者采用常規(guī)治療方法，同時(shí)給予貝拉普利治療，研究組42例患者在對(duì)照組治療基礎(chǔ)上給予丹參酮ⅡA靜脈滴注治療，比較兩組患者治療效果及對(duì)患者腦鈉肽、D-二聚體水平的影響。 結(jié)果 研究組有效率（85.71%）顯著高于對(duì)照組（65.85%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；兩組患者治療后氧分壓（PaO2）、二氧化碳分壓（PaCO2）、血氧飽和度（SaO2）指標(biāo)與治療前比較，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；研究組治療后PaO2、PaCO2指標(biāo)改善程度優(yōu)于對(duì)照組（P<0.05）；兩組患者治療后LVEF顯著高于治療前，腦鈉肽、D-二聚體指標(biāo)顯著低于治療前，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；研究組LVEF、腦鈉肽、D-二聚體指標(biāo)改善程度顯著優(yōu)于對(duì)照組（P<0.05）。 結(jié)論 丹參酮ⅡA治療慢性肺源性心臟病急性加重期的療效確切，能有效提高心功能，降低血清腦鈉肽水平，改善血液循環(huán)。
　　[關(guān)鍵詞] 丹參酮ⅡA；肺源性心臟��；急性加重期；腦鈉肽；D-二聚體
　　[中圖分類號(hào)] R541.5 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1673-9701（2018）08-0001-03
　　Effect of tanshinone ⅡA on brain natriuretic peptide and D-dimmer levels in patients with chronic pulmonary heart disease in acute exacerbation stage
　　CHU Weiwei1 ZHANG Zhi1 LIU Yi1 GONG Dandan2
　　1.Third Department of Cardiology， Dalian Third People"s Hospital， Dalian 116031， China； 2.Third Department of Cardiology， Dalian Central Hospital， Dalian 116000， China
　　[Abstract] Objective To explore the effects of tanshinone ⅡA on the treatment of chronic patients with pulmonary heart disease in acute exacerbation stage， and to study its effects on brain natriuretic peptide and D-dimer levels. Methods A total of 83 patients with chronic pulmonary heart disease in acute exacerbation stage who admitted in our hospital from January 2015 to January 2017 were selected and divided into study group and control group， 41 cases in the control group were given conventional treatment and Belapril treatment， and the 42 patients in the study group were given tanshinone ⅡA intravenous infusion therapy on the basis of the control group. The therapeutic efficacy and the effects on the brain natriuretic peptide and D-dimer levels of two groups were compared. Results The effective rate（85.71%） in the study group was significantly higher than that（65.85%） in the control group， and the difference was statistically significant（P<0.05）. There were significant differences in partial pressure of oxygen（PaO2）， carbon dioxide partial pressure（PaCO2） and oxygen saturation（SaO2） index after treatment compared with those before treatment in two groups（P<0.05）. The improvement of PaO2 and PaCO2 indexes after treatment in the study was better than that in the control group（P<0.05）. The LVEF level in two groups after treatment was significantly higher than that before treatment， and the brain natriuretic peptide and D-dimmer levels in two groups after treatment were significantly lower than those before treatment（P<0.05）. The improvement of LVEF， brain natriuretic peptide and D-dimmer levels in the study group was significantly better than that in the control group（P<0.05）. Conclusion Tanshinone ⅡA has exact effect in treatment of patients with chronic pulmonary heart disease in acute exacerbation stage， it can effectively improve heart function， reduce serum brain natriuretic peptide level， and can improve blood circulation.

相關(guān)熱詞搜索：心臟病 加重 患者 影響 丹參酮